Sun Pharma gets favourable verdict in antitrust-litigation in U.S.
Sun Pharmaceutical Industries has won an antitrust lawsuit in the U.S. regarding a 2008 patent settlement for the generic drug Lipitor. The appellate court affirmed a lower court's decision to grant summary judgment in favor of the company.
Why it matters
This legal victory removes a significant litigation burden for the pharmaceutical company and clarifies the status of generic drug patent settlements.
Sun Pharmaceutical Industries on Monday (August 17, 2026) said an appellate court in the United States has passed a judgment in favour of the company and its subsidiaries in the antitrust litigation, in the U.S., relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin).
The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the company and its subsidiaries. The appellate court has also affirmed the District Court’s orders denying class certification as to the plaintiffs, the generic drugmaker said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in